he global fight against HIV has reached a historic milestone with the development of Lenacapavir, a long-acting injectable pre-exposure prophylaxis (PrEP) that demonstrates up to 99.9% efficacy in preventing infection. The United States Food and Drug Administration (FDA) has approved the medication for adults and adolescents, while the World Health Organization (WHO) hailed it as one of the most significant advancements in modern HIV prevention.

Administered as a subcutaneous injection just once every six months, Lenacapavir offers a revolutionary alternative to daily oral PrEP regimens. Medical authorities emphasize that while Lenacapavir is not a cure for established HIV infection, its unparalleled efficacy in blocking transmission provides a powerful new tool to curtail global infection rates and enhance long-term treatment adherence.